Among these, CRL4CRBN—the most representative E3 ubiquitin ligase in MM therapy—mediates the degradation of key transcription factors IKZF1/3 through its targeted drugs lenalidomide and pomalidomide, which alter CRBN’s substrate specificity, ultimately suppressing MM cell growth (Weathington and Mallampalli, 2014). The gene discussed is CRBN; the disease is Miyoshi myopathy.